Trutect gives parvo care a targeted treatment option

Canine parvovirus now has a more established targeted treatment option, with Elanco’s monoclonal antibody therapy moving from conditional approval to full USDA approval under the brand name Trutect in December 2025. The product, formerly marketed as Canine Parvovirus Monoclonal Antibody, was first conditionally approved in May 2023 for treatment of active infection, and its label was expanded in June 2025 to include passive immunity for exposed puppies. USDA product records list the licensed product as anivovetmab, trade name Trutect. In Elanco’s real-world data, 93% of treated puppies survived, and treated patients spent an average of 1.87 fewer days in the hospital. (elanco.com)

Why it matters: For veterinary teams, this marks a meaningful shift from parvo care that has historically depended almost entirely on supportive therapy. USDA licensure materials describe efficacy data showing 0 of 21 treated dogs died in the pivotal treatment study, compared with 4 of 7 controls, and the label expansion for passive immunity was supported by a study in which 0 of 19 treated dogs met disease criteria after challenge, versus 5 of 5 controls. Separate shelter data presented at ISCAID 2024 suggest the monoclonal antibody may also shorten hospitalization and isolation time in naturally occurring cases, even when survival differences were not statistically significant in that retrospective setting. That combination could matter operationally for ERs, GP clinics, and shelters managing isolation space, staffing strain, and cost-sensitive pet parent decisions. (aphis.usda.gov)

What to watch: Watch for broader protocol adoption, post-licensure field data in naturally infected dogs, and how practices use the prevention indication for exposed puppies in shelters and outbreak settings. (elanco.com)